Theravance Biopharma (TBPH) Other financing activities (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Other financing activities of $241000.0 for Q1 2026, down 50.61% quarter-over-quarter from $488000.0 in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Other financing activities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Other financing activities for 14 consecutive years, with $241000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $241000.0; the TTM figure through Mar 2026 stood at $862000.0 (changed N/A YoY), while the FY2025 annual figure was $766000.0, up 50.79% from the prior year.
- Other financing activities eased to $241000.0 in Q1 2026 per TBPH's latest filing, from $488000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $21.0 million in Q4 2022 and bottomed at -$20.7 million in Q3 2022.
- Historically, Other financing activities has averaged $192714.3 across 5 years, with a median of $173000.0 in 2023.
- On a YoY basis, Other financing activities climbed as much as 3375.33% in 2022 and fell as far as 823.7% in 2022.
- Theravance Biopharma's Other financing activities stood at $21.0 million in 2022, then sank by 99.18% to $173000.0 in 2023, then retreated by 23.12% to $133000.0 in 2024, then soared by 266.92% to $488000.0 in 2025, then tumbled by 50.61% to $241000.0 in 2026.
- Business Quant data shows TBPH's Other financing activities at $241000.0 in Q1 2026, $488000.0 in Q4 2025, and $133000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 241,000.00 |
| Dec 31, 2025 | 488,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Dec 31, 2023 | 173,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2022 | -20.68 Mn |
| Dec 31, 2021 | 604,000.00 |
| Jun 30, 2021 | 2.86 Mn |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | -19.34 Mn |
| Jun 30, 2020 | 2.34 Mn |
| Mar 31, 2020 | 203,000.00 |
| Dec 31, 2019 | 501,000.00 |
| Sep 30, 2019 | 368,000.00 |
| Jun 30, 2019 | 2.35 Mn |
| Mar 31, 2019 | 254,000.00 |
| Dec 31, 2018 | 1.43 Mn |
| Jun 30, 2018 | 2.71 Mn |
| Mar 31, 2018 | 35,000.00 |